RAPPORT THERAPEUTICS INC
RAPP · NASDAQ
Updated at 2026-10-14 08:42:09
- Today's High
- $30.01
- Today’s Low
- $28.68
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $30.65
- Previous Close
- $30.15
- Volume
- 127.13K
- Market Cap
- $1.44B
- P/E Ratio
- --
- EPS
- $-3.04
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 99 HIGH STREET, BOSTON, MA, UNITED STATES, 02110
- Country
- US
- Listing Date
- 2024-06-07
- Fiscal Year End
- December
- Shares Outstanding
- 47.83M
- CIK
- 0002012593
- Website
- www.rapportrx.com
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated cognitive disorders. Utilizing proprietary drug candidates and cutting-edge technology platforms, the firm is focused on meeting significant unmet medical needs through comprehensive scientific research and clinical trials. With a robust pipeline of innovative treatment options, Rapport Therapeutics is strategically poised to reshape the treatment paradigm for individuals facing the challenges of cognitive impairments, enhancing patient quality of life and contributing to the broader healthcare landscape.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$20M
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$60.8M
2026-03-31
$44.21M
2025-12-31
$38.5M
2025-09-30
$29.98M
Net Income
2026-06-30
-$56.61M
2026-03-31
-$19.85M
2025-12-31
-$33.76M
2025-09-30
-$26.92M
Net Profit Margin
2026-06-30
--
2026-03-31
-99.28%
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-1.19
2026-03-31
$-0.42
2025-12-31
$-0.72
2025-09-30
$-0.71
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$56.4M
2026-03-31
-$23.98M
2025-12-31
-$38.24M
2025-09-30
-$29.73M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $20M | $0 | $0 |
| Operating Expenses | $60.8M | $44.21M | $38.5M | $29.98M |
| Net Income | -$56.61M | -$19.85M | -$33.76M | -$26.92M |
| Net Profit Margin | -- | -99.28% | -- | -- |
| Earnings Per Share | $-1.19 | $-0.42 | $-0.72 | $-0.71 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$56.4M | -$23.98M | -$38.24M | -$29.73M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.